Physician profile
Robert J Perin
NPI 1679564959
$1,003.14
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $119 · 2021: $12.59 · 2022: $48.05 · 2023: $58.66 · 2024: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $219.25 | 2019-2024 | Airsupra |
| Optinose US, INC. | $124.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.66 | 2019 | |
| Kaleo, INC. | $41.06 | 2019 | |
| Amgen INC. | $37.85 | 2022-2023 | Tezspire |
| Genzyme Corporation | $29.63 | 2019 | |
| Merck Sharp & Dohme LLC | $27.26 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $26.01 | 2019 | |
| Phadia US INC. | $25.77 | 2023 | Immunocap |
| Genentech USA, INC. | $19.04 | 2019 | |
| Csl Behring | $17.90 | 2019 | |
| Blueprint Medicines Corporation | $14.63 | 2023 | Ayvakit |
| Pharming Healthcare, INC. | $14.40 | 2024 | Ruconest |
| Leo Pharma INC. | $13.79 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.